Melissa Lumish, MD
Hematology & Oncology · New York, NYNPI 1033568324
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. GSK accounts for 86.3% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $3,905, more than ten times the $194 reported in 2019.
Across 14 payments — averaging $305.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- Amgen$194
- Array Biopharma Inc$139
- Boston Scientific$90
- Intera Oncology, Inc$74
- Genentech USA, Inc.$27
- plus $63 from 3 others
Across 3 payments — averaging $29,941 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$90K
What the payments were for
- Consulting fees$2,53859%
- Travel & lodging$1,00623%
- Food & beverage$54313%
- Education$1945%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $3,694 |
| Amgen | 2 | $194 |
| Array Biopharma Inc | 1 | $139 |
| Boston Scientific | 1 | $90 |
| Intera Oncology, Inc | 1 | $74 |
| Genentech USA, Inc. | 1 | $27 |
| Novartis | 1 | $24 |
| Caris MPI, Inc. | 1 | $24 |
| Merck | 1 | $15 |
How this compares
$4,280 in reported general payments places this provider in the 65th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 19 | $30,477 |
| Ondansetron Hcl | 38 | $1,244 |
| LoperamideLoperamide Hcl | 21 | $470 |
| Prochlorperazine Maleate | 22 | $248 |
| Pantoprazole Sodium | 17 | $156 |
| Potassium Chloride | 13 | $129 |
| Oxycodone Hcl | 17 | $127 |
| Dexamethasone | 14 | $96 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.